Health Library · Cost & Access
Why CAR-T Treatment Can Be More Affordable in Türkiye
Educational cost overview · Updated 2026
CAR-T cell therapy is one of the most expensive treatments in modern medicine. In the United States, list prices for commercial CAR-T products commonly fall in the range of approximately USD 373,000 to 475,000 for the product alone, and the total cost of care (hospital stay, toxicity management, diagnostics) is often substantially higher. In Western Europe, episode costs frequently land in the hundreds of thousands of euros.
Against that background, many patients and families ask whether treatment in Türkiye can be more affordable — and if so, why. This article explains the main cost drivers of CAR-T therapy and how local manufacturing through technology transfer can change the economics without automatically changing the quality standards of the product.
What makes CAR-T so expensive in major markets
The high price of commercial CAR-T in the US and Europe is the result of several overlapping factors:
- Complex manufacturing — each dose is an individualized living product made from the patient’s own cells under strict GMP conditions.
- Research and development costs — years of preclinical work, clinical trials and regulatory submissions are built into the price of approved products.
- Specialized facilities and skilled labor — cleanrooms, quality-control laboratories and highly trained staff are expensive to operate.
- Logistics of a living medicine — when manufacturing is centralized far from the patient, cold-chain shipping, customs and tight timing add cost and risk.
- Hospital and supportive care — the product price is only part of the bill. Inpatient monitoring, treatment of cytokine release syndrome or infections, and follow-up care add significantly to the total.
- Market and reimbursement structures — list prices reflect negotiations with insurers and health systems in high-income countries.
How local manufacturing can reduce cost
When CAR-T is manufactured closer to the patient through a technology-transfer model, several cost components can change:
1. Reduced long-distance logistics
Shipping a living cell product across continents requires specialized couriers, temperature control, customs clearance and contingency planning. Local manufacturing shortens or removes much of this chain. Lower logistics complexity can translate into lower operational cost and less risk of delay or product loss.
2. Different overhead and pricing environment
Labor, facility and administrative costs differ between regions. A manufacturing operation based in Türkiye operates in a different cost structure than one based in the United States or Western Europe. When the process itself is transferred from an already-developed product, the receiving site does not have to recover the full original R&D investment in the same way a first-in-class commercial launch does.
3. Technology transfer of an approved product
Building a completely new CAR-T product from early research through Phase 3 trials is extremely expensive. Technology transfer of a product that already has regulatory approval and clinical data allows local production to start from a more mature process. The focus shifts to validating and operating that process under local GMP conditions rather than funding an entire discovery and late-stage development program from zero.
4. Integrated clinical pathway
When collection, manufacturing and infusion are coordinated within a shorter geographic and operational loop, some of the coordination and waiting-time costs associated with international referral can be reduced.
Approximate range discussed for the emerging local pathway
In the context of the technology-transfer manufacturing pathway linked to Biruni Cell Therapy, a target treatment cost in the region of approximately USD 250,000 has been discussed as a more accessible figure compared with typical US list prices and many Western European episode costs. This figure is indicative, not a fixed public price list. The final cost for any patient depends on the specific clinical pathway, hospital services, length of stay, management of side effects and individual circumstances.
What the lower cost does not mean
A more accessible price is attractive, but it should not be interpreted as:
- A guarantee that every patient will pay exactly the same amount
- Evidence that quality standards have been reduced
- A promise that insurance or national health systems will cover the treatment
- A substitute for careful medical eligibility assessment
Quality is determined by the manufacturing process, analytical release testing, GMP compliance and the experience of the clinical team — not by the price tag alone. A technology-transfer model aims to keep those quality elements while improving the cost and logistics profile.
Cost is only one part of the decision
Even when the financial difference is significant, the decision to pursue CAR-T should still rest on medical grounds:
- Is the disease type and stage appropriate for current CAR-T indications?
- Has the patient received prior therapies that make CAR-T a logical next step?
- Is the patient fit enough for the treatment and its potential side effects?
- Is the treating center prepared to manage cytokine release syndrome, neurologic events and infections?
- Is the manufacturing route transparent about its process, origin data and quality controls?
Cost can make an option more realistic for a family or a health system. It should not be the only reason to choose or reject a therapy.
Practical advice for patients comparing options
- Ask for a clear breakdown of what is included (product, hospital stay, medications for side effects, follow-up visits).
- Clarify whether the quoted figure is an estimate or a package, and what happens if a longer hospital stay or intensive care is required.
- Compare the clinical evidence of the specific product being offered, not only the price.
- Confirm which hospital will perform collection, infusion and monitoring.
- Understand travel, accommodation and caregiver costs if treatment is away from home.
Bottom line
CAR-T therapy is expensive everywhere because it is complex to make and complex to deliver. Local manufacturing through technology transfer of an already-approved product can remove some of the logistics burden and operate within a different cost structure, which helps explain why treatment in Türkiye can be positioned at a lower overall cost than typical US or Western European figures — while still aiming to meet GMP quality expectations.
The approximate USD 250,000 range discussed for the emerging local pathway is substantially below many Western list and episode prices, but every patient’s final cost and medical suitability must be evaluated individually.